Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 67 articles:
HTML format
Text format



Single Articles


    March 2017
  1. DENSLOW A, Switalska M, Nowak M, Maciejewska M, et al
    The effects of 1,4-dimethylpyridine in metastatic prostate cancer in mice.
    BMC Cancer. 2017;17:177.
    PubMed     Text format     Abstract available


  2. CHEN L, Wolff DW, Xie Y, Lin MF, et al
    Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5.
    BMC Cancer. 2017;17:179.
    PubMed     Text format     Abstract available


  3. LUNDON DJ, Boland A, Prencipe M, Hurley G, et al
    The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
    BMC Cancer. 2017;17:163.
    PubMed     Text format     Abstract available


    February 2017
  4. CHEVRIER M, Bobbala D, Villalobos-Hernandez A, Khan MG, et al
    Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.
    BMC Cancer. 2017;17:157.
    PubMed     Text format     Abstract available


  5. KUMAR SR, Bryan JN, Esebua M, Amos-Landgraf J, et al
    Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.
    BMC Cancer. 2017;17:158.
    PubMed     Text format     Abstract available


  6. LAZARO-IBANEZ E, Lunavat TR, Jang SC, Escobedo-Lucea C, et al
    Distinct prostate cancer-related mRNA cargo in extracellular vesicle subsets from prostate cell lines.
    BMC Cancer. 2017;17:92.
    PubMed     Text format     Abstract available


    January 2017
  7. DEMARK-WAHNEFRIED W, Nix JW, Hunter GR, Rais-Bahrami S, et al
    Erratum to: Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing pr
    BMC Cancer. 2017;17:71.
    PubMed     Text format    


  8. BATAI K, Murphy AB, Ruden M, Newsome J, et al
    Race and BMI modify associations of calcium and vitamin D intake with prostate cancer.
    BMC Cancer. 2017;17:64.
    PubMed     Text format     Abstract available


  9. BAGULEY BJ, Skinner TL, Leveritt MD, Wright OR, et al
    Nutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: a study protocol.
    BMC Cancer. 2017;17:1.
    PubMed     Text format     Abstract available


    November 2016
  10. LI X, Ji Y, Han G, Li X, et al
    MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer.
    BMC Cancer. 2016;16:894.
    PubMed     Text format     Abstract available


  11. ZHAO J, Stockwell T, Roemer A, Chikritzhs T, et al
    Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis.
    BMC Cancer. 2016;16:845.
    PubMed     Text format     Abstract available


    October 2016
  12. JOHNSTON E, Pye H, Bonet-Carne E, Panagiotaki E, et al
    INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer.
    BMC Cancer. 2016;16:816.
    PubMed     Text format     Abstract available


  13. BJERRE E, Bruun DM, Tolver A, Brasso K, et al
    Effectiveness of community-based football compared to usual care in men with prostate cancer: Protocol for a randomised, controlled, parallel group, multicenter superiority trial (The FC Prostate Community Trial).
    BMC Cancer. 2016;16:767.
    PubMed     Text format     Abstract available


    January 2016
  14. FONAGER RF, Zacho HD, Langkilde NC, Petersen LJ, et al
    (18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study.
    BMC Cancer. 2016;16:10.
    PubMed     Text format     Abstract available


  15. GRAVINA GL, Mancini A, Sanita P, Vitale F, et al
    Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models.
    BMC Cancer. 2016;16:8.
    PubMed     Text format    


  16. KAWAHARA T, Yokomizo Y, Ito Y, Ito H, et al
    Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer.
    BMC Cancer. 2016;16:111.
    PubMed     Text format     Abstract available


  17. UEMURA K, Miyoshi Y, Kawahara T, Yoneyama S, et al
    Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.
    BMC Cancer. 2016;16:109.
    PubMed     Text format     Abstract available


  18. MIYOSHI Y, Yoneyama S, Kawahara T, Hattori Y, et al
    Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.
    BMC Cancer. 2016;16:128.
    PubMed     Text format     Abstract available


  19. LINDSAY CR, Le Moulec S, Billiot F, Loriot Y, et al
    Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
    BMC Cancer. 2016;16:168.
    PubMed     Text format     Abstract available


  20. HOYNE G, Rudnicka C, Sang QX, Roycik M, et al
    Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer.
    BMC Cancer. 2016;16:151.
    PubMed     Text format     Abstract available


  21. CARTER SL, Centenera MM, Tilley WD, Selth LA, et al
    IkappaBalpha mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.
    BMC Cancer. 2016;16:141.
    PubMed     Text format     Abstract available


  22. MENG F, Zhu S, Zhao J, Vados L, et al
    Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.
    BMC Cancer. 2016;16:180.
    PubMed     Text format     Abstract available


  23. CARTER SL, Centenera MM, Tilley WD, Selth LA, et al
    Erratum to: IkappaBalpha mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.
    BMC Cancer. 2016;16:177.
    PubMed     Text format    


  24. MIKAH P, Krabbe LM, Eminaga O, Herrmann E, et al
    Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
    BMC Cancer. 2016;16:214.
    PubMed     Text format     Abstract available


  25. TAI SY, Hsieh HM, Huang SP, Wu MT, et al
    Hair dye use, regular exercise, and the risk and prognosis of prostate cancer: multicenter case-control and case-only studies.
    BMC Cancer. 2016;16:242.
    PubMed     Text format     Abstract available


  26. WANG J, Yang ZH, Chen H, Li HH, et al
    Nemo-like kinase as a negative regulator of nuclear receptor Nurr1 gene transcription in prostate cancer.
    BMC Cancer. 2016;16:257.
    PubMed     Text format     Abstract available


  27. NAKAMURA S, Murakami N, Inaba K, Wakita A, et al
    After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
    BMC Cancer. 2016;16:296.
    PubMed     Text format     Abstract available


  28. SCHELTEMA MJ, van den Bos W, de Bruin DM, Wijkstra H, et al
    Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    BMC Cancer. 2016;16:299.
    PubMed     Text format     Abstract available


  29. TAKEDA K, Hara N, Nishiyama T, Tasaki M, et al
    Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    BMC Cancer. 2016;16:332.
    PubMed     Text format     Abstract available


  30. WANG Y, Xu F, Pan J, Zhu Y, et al
    Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
    BMC Cancer. 2016;16:329.
    PubMed     Text format     Abstract available


  31. DE NUNZIO C, Simone G, Brassetti A, Mastroianni R, et al
    Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
    BMC Cancer. 2016;16:407.
    PubMed     Text format     Abstract available


  32. RUSSNES KM, Moller E, Wilson KM, Carlsen M, et al
    Total antioxidant intake and prostate cancer in the Cancer of the Prostate in Sweden (CAPS) study. A case control study.
    BMC Cancer. 2016;16:438.
    PubMed     Text format     Abstract available


  33. LIANG M, Zhan F, Zhao J, Li Q, et al
    CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.
    BMC Cancer. 2016;16:504.
    PubMed     Text format     Abstract available


  34. KERR L, Rewhorn MJ, Longmuir M, Fraser S, et al
    A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer.
    BMC Cancer. 2016;16:529.
    PubMed     Text format     Abstract available


  35. RUANE-MCATEER E, O'Sullivan J, Porter S, Venderbos L, et al
    An exploration of men's experiences of undergoing active surveillance for favourable-risk prostate cancer: A mixed methods study protocol.
    BMC Cancer. 2016;16:586.
    PubMed     Text format     Abstract available


  36. YAMOAH K, Zeigler-Johnson CM, Jeffers A, Malkowicz B, et al
    The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer.
    BMC Cancer. 2016;16:557.
    PubMed     Text format     Abstract available


  37. RUSECKAITE R, Beckmann K, O'Callaghan M, Roder D, et al
    A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease.
    BMC Cancer. 2016;16:607.
    PubMed     Text format     Abstract available


  38. AMARAL CL, Freitas LB, Tamura RE, Tavares MR, et al
    S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.
    BMC Cancer. 2016;16:602.
    PubMed     Text format     Abstract available


  39. SCHOFIELD P, Gough K, Lotfi-Jam K, Bergin R, et al
    Nurse-led group consultation intervention reduces depressive symptoms in men with localised prostate cancer: a cluster randomised controlled trial.
    BMC Cancer. 2016;16:637.
    PubMed     Text format     Abstract available


  40. TSOURLAKIS MC, Stender A, Quaas A, Kluth M, et al
    Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.
    BMC Cancer. 2016;16:641.
    PubMed     Text format     Abstract available


  41. WANG K, Wu G, Li J, Song W, et al
    Role of vitamin D receptor gene Cdx2 and Apa1 polymorphisms in prostate cancer susceptibility: a meta-analysis.
    BMC Cancer. 2016;16:674.
    PubMed     Text format     Abstract available


  42. HEIR T, Falk RS, Robsahm TE, Sandvik L, et al
    Cholesterol and prostate cancer risk: a long-term prospective cohort study.
    BMC Cancer. 2016;16:643.
    PubMed     Text format     Abstract available


  43. LEE SO, Kim JS, Lee MS, Lee HJ, et al
    Anti-cancer effect of pristimerin by inhibition of HIF-1alpha involves the SPHK-1 pathway in hypoxic prostate cancer cells.
    BMC Cancer. 2016;16:701.
    PubMed     Text format     Abstract available


  44. DAYYANI F, Zurita AJ, Nogueras-Gonzalez GM, Slack R, et al
    The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study.
    BMC Cancer. 2016;16:721.
    PubMed     Text format     Abstract available


  45. MIKI K, Sasaki H, Kido M, Takahashi H, et al
    A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    BMC Cancer. 2016;16:708.
    PubMed     Text format     Abstract available


    May 2015
  46. TOMIOKA A, Tanaka N, Yoshikawa M, Miyake M, et al
    Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
    BMC Cancer. 2015;15:420.
    PubMed     Text format     Abstract available


    January 2015
  47. THALGOTT M, Rack B, Eiber M, Souvatzoglou M, et al
    Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
    BMC Cancer. 2015;15:458.
    PubMed     Text format     Abstract available


  48. BURDELSKI C, Menan D, Tsourlakis MC, Kluth M, et al
    The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    BMC Cancer. 2015;15:538.
    PubMed     Text format     Abstract available


  49. KISSICK HT, On ST, Dunn LK, Sanda MG, et al
    The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells.
    BMC Cancer. 2015;15:604.
    PubMed     Text format     Abstract available


  50. BAHIG H, Taussky D, Delouya G, Nadiri A, et al
    Neutrophil count is associated with survival in localized prostate cancer.
    BMC Cancer. 2015;15:594.
    PubMed     Text format     Abstract available


  51. JEON JY, Kim SW, Park KC, Yun M, et al
    The bifunctional autophagic flux by 2-deoxyglucose to control survival or growth of prostate cancer cells.
    BMC Cancer. 2015;15:623.
    PubMed     Text format     Abstract available


  52. RUBIO-BRIONES J, Borque A, Esteban LM, Casanova J, et al
    Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.
    BMC Cancer. 2015;15:633.
    PubMed     Text format     Abstract available


  53. SUPIOT S, Rio E, Pacteau V, Mauboussin MH, et al
    OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.
    BMC Cancer. 2015;15:646.
    PubMed     Text format     Abstract available


  54. DEMIDENKO R, Razanauskas D, Daniunaite K, Lazutka JR, et al
    Frequent down-regulation of ABC transporter genes in prostate cancer.
    BMC Cancer. 2015;15:683.
    PubMed     Text format     Abstract available


  55. RODRIGUEZ-BERRIGUETE G, Torrealba N, Ortega MA, Martinez-Onsurbe P, et al
    Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy.
    BMC Cancer. 2015;15:809.
    PubMed     Text format     Abstract available


  56. XU X, Chen X, Hu H, Dailey AB, et al
    Current opinion on the role of testosterone in the development of prostate cancer: a dynamic model.
    BMC Cancer. 2015;15:806.
    PubMed     Text format     Abstract available


  57. FUJIMURA T, Takahashi S, Kume H, Urano T, et al
    Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial.
    BMC Cancer. 2015;15:836.
    PubMed     Text format     Abstract available


  58. WANG A, Obertova Z, Brown C, Karunasinghe N, et al
    Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
    BMC Cancer. 2015;15:837.
    PubMed     Text format     Abstract available


  59. DETCHOKUL S, Elangovan A, Crampin EJ, Davis MJ, et al
    Network analysis of an in vitro model of androgen-resistance in prostate cancer.
    BMC Cancer. 2015;15:883.
    PubMed     Text format     Abstract available


  60. ZHANG X, Chen M, Zou P, Kanchana K, et al
    Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells.
    BMC Cancer. 2015;15:866.
    PubMed     Text format     Abstract available


  61. CAO W, Li F, Yao J, Yu J, et al
    Prostate specific G protein coupled receptor is associated with prostate cancer prognosis and affects cancer cell proliferation and invasion.
    BMC Cancer. 2015;15:915.
    PubMed     Text format     Abstract available


  62. GRAVINA GL, Mancini A, Sanita P, Vitale F, et al
    KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and surviving in prostate cancer models.
    BMC Cancer. 2015;15:941.
    PubMed     Text format     Abstract available


  63. CICIONE A, De Nunzio C, Tubaro A, Cantiello F, et al
    Metabolic syndrome diagnosis and widespread high grade prostatic intraepithelial neoplasia significantly increase prostate cancer risk: results from a multicenter biopsy study.
    BMC Cancer. 2016;16:59.
    PubMed     Text format     Abstract available


  64. HSIAO JJ, Ng BH, Smits MM, Wang J, et al
    Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
    BMC Cancer. 2015;15:204.
    PubMed     Text format     Abstract available


  65. MENGUAL L, Lozano JJ, Ingelmo-Torres M, Izquierdo L, et al
    Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers.
    BMC Cancer. 2016;16:76.
    PubMed     Text format     Abstract available


  66. DEMARK-WAHNEFRIED W, Nix JW, Hunter GR, Rais-Bahrami S, et al
    Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy
    BMC Cancer. 2016;16:61.
    PubMed     Text format     Abstract available


  67. CAMPTON DE, Ramirez AB, Nordberg JJ, Drovetto N, et al
    High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining.
    BMC Cancer. 2015;15:360.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: